Kate Bowie , 2025-09-01 15:31:00
Switching from aspirin to clopidogrel could reduce the risk of myocardial infarction, stroke, or death by an extra 14% in patients with coronary artery disease (CAD), a Lancet study has found.1
The researchers—who presented their findings at the 2025 European Society of Cardiology congress in Madrid—said that clopidogrel should be the preferred long term antiplatelet treatment for patients with CAD.
The study analysed seven randomised trials comparing clopidogrel and aspirin in people with CAD, and looked at individual patient data for a total of 28 982 study participants (14 507 assigned to clopidogrel, 14 475 assigned to aspirin). They used a shared log-normal frailty statistical model …